Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Prime Medicine, Inc. is a biotechnology company focused on delivering genetic therapies for a wide range of diseases using its proprietary Prime Editing technology. This innovative platform allows for precise DNA editing without causing double-stranded breaks, enabling targeted genetic corrections. The company is actively developing treatments for genetic diseases and certain cancers through internal research and collaborations.
AI-generated summary. Not investment advice.